Onconetix Inc
ONCO1.190USD
+0.020+1.71%
收盘 02/09, 16:00（美东）报价延迟15分钟
328.70K总市值
0.00市盈率 TTM
关于 Onconetix Inc 公司
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Onconetix Inc简介
公司代码ONCO
公司名称Onconetix Inc
上市日期Feb 18, 2022
CEOFedasz (Karina M)
员工数量5
证券类型Ordinary Share
年结日Feb 18
公司地址201 E. Fifth Street
城市CINCINNATI
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编45202
电话15136204101
网址https://www.onconetix.com/
公司代码ONCO
上市日期Feb 18, 2022
CEOFedasz (Karina M)
Onconetix Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
658.00
-39.00%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
658.00
-39.00%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q1
FY2024
FY2023
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Switzerland
94.38K
92.87%
United Kingdom
7.25K
7.13%
United States
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 2月3日 周二
更新时间: 2月3日 周二
持股股东
股东类型
持股股东
持股股东
占比
Altos Venture AG
17.57%
DRW Securities, LLC
3.97%
Citadel Advisors LLC
1.01%
UBS Financial Services, Inc.
0.59%
Schiess (Ralph)
0.51%
其他
76.35%
持股股东
持股股东
占比
Altos Venture AG
17.57%
DRW Securities, LLC
3.97%
Citadel Advisors LLC
1.01%
UBS Financial Services, Inc.
0.59%
Schiess (Ralph)
0.51%
其他
76.35%
股东类型
持股股东
占比
Corporation
18.44%
Investment Advisor
4.57%
Individual Investor
1.14%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.21%
Research Firm
0.01%
其他
74.52%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
31
91.66K
5.89%
+62.90K
2025Q3
31
22.38K
5.65%
+17.05K
2025Q2
47
63.91K
38.67%
+44.58K
2025Q1
54
64.94K
25.23%
+43.00K
2024Q4
54
5.57M
44.93%
+3.81M
2024Q3
55
5.45M
45.59%
+5.19M
2024Q2
54
145.05K
20.85%
-52.13K
2024Q1
56
197.34K
30.36%
-46.00
2023Q4
55
198.08K
30.63%
+320.00
2023Q3
52
191.81K
46.53%
-6.38K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Altos Venture AG
273.23K
17.57%
+241.51K
+761.46%
Jul 14, 2025
DRW Securities, LLC
61.78K
3.97%
+61.78K
--
Sep 30, 2025
Citadel Advisors LLC
15.63K
1.01%
+15.63K
--
Sep 30, 2025
UBS Financial Services, Inc.
5.51K
0.35%
+2.71K
+97.28%
Sep 30, 2025
Schiess (Ralph)
7.92K
0.51%
--
--
Dec 12, 2025
Bruhlmann (Christian)
7.19K
0.46%
--
--
Dec 12, 2025
Scablis AG
6.85K
0.44%
+6.85K
--
Sep 24, 2024
New Horizon Health Ltd
6.74K
0.43%
+6.74K
--
Sep 24, 2024
Tower Research Capital LLC
1.57K
0.1%
+1.24K
+375.15%
Sep 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
公告日期
除权除息日
类型
比率
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
